WallStreetZenWallStreetZen

NASDAQ: SMMT
Summit Therapeutics Inc Stock Ownership - Who owns Summit Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Summit Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Mahkam ZanganehCo-Chief Executive Officer2024-10-03315,681$1.58
$498.78kBuy
Bhaskar AnandChief Accounting Officer2024-09-1122,026$22.70
$499.99kBuy
Robert W. DugganCo-Chief Executive Officer2024-09-113,325,991$22.70
$75.50MBuy
Jeff HuberDirector2024-09-1144,052$22.70
$999.98kBuy
Manmeet Singh SoniCOO and CFO2024-09-1144,052$22.70
$999.98kBuy
Mahkam ZanganehCo-Chief Executive Officer2024-09-1144,052$22.70
$999.98kBuy
Mahkam ZanganehChief Executive Officer2024-03-2726,000$3.72
$96.72kBuy
Mahkam ZanganehChief Executive Officer2024-03-2720,000$3.71
$74.20kBuy
Mahkam ZanganehChief Executive Officer2024-03-2734,321$3.72
$127.67kBuy
Mahkam ZanganehChief Executive Officer2024-03-2630,000$3.75
$112.50kBuy

1 of 2

SMMT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SMMT insiders and whales buy or sell their stock.

SMMT Shareholders

What type of owners hold Summit Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Robert W. Duggan76.14%551,695,096$11.01BInsider
Mahkam Zanganeh9.69%70,196,335$1.40BInsider
Baker Bros Advisors LP3.21%23,222,222$463.28MInstitution
Yu Xia2.97%21,523,530$429.39MInsider
Maky Zanganeh2.06%14,915,775$297.57MInsider
Vanguard Group Inc1.22%8,818,463$175.93MInstitution
Blackrock Inc1.09%7,898,585$157.58MInstitution
Fmr LLC1.04%7,565,427$150.93MInstitution
State Street Corp0.57%4,123,137$82.26MInstitution
Manmeet Singh Soni0.42%3,020,242$60.25MInsider

1 of 3

SMMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SMMT9.83%90.17%Net BuyingNet Buying
GMAB73.67%0.00%
UTHR87.89%12.11%Net SellingNet Buying
BMRN96.78%1.65%Net SellingNet Selling
INSM82.35%17.65%Net SellingNet Selling
View Top Biotech Stocks

Summit Therapeutics Stock Ownership FAQ

Who owns Summit Therapeutics?

Summit Therapeutics (NASDAQ: SMMT) is owned by 9.96% institutional shareholders, 91.36% Summit Therapeutics insiders, and 0.00% retail investors. Robert W. Duggan is the largest individual Summit Therapeutics shareholder, owning 551.70M shares representing 76.14% of the company. Robert W. Duggan's Summit Therapeutics shares are currently valued at $11.17B.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.